期刊文献+

拓扑替康联合卡铂治疗复发性小细胞肺癌临床观察 被引量:6

Topotecan in combination with carboplatin in the treatment of recurrent small cell lung cancer
下载PDF
导出
摘要 目的:观察盐酸拓扑替康联合卡铂治疗复发性小细胞肺癌的疗效及不良反应。方法:对29例复发的小细胞肺癌患者采用CT方案化疗:拓普替康1.2mg/m2,d1-5;卡铂300mg/m2,d5,21天为1周期,至少治疗2周期。结果:CR 1例,PR 11例,SD 12例,PD 5例,总有效率为41.38%,其中敏感型和难治型复发患者的有效率分别为47.62%和25%。结论:拓普替康与卡铂作为二线方案治疗复发性小细胞肺癌,疗效确切。主要不良反应为血液学毒性,及时应用集落刺激因子,可耐受治疗。 Objective:To observe the effect and side effects of topotecan in combination with carboplatin in the treatment of recurrent small cell lung cancer.Methods:Twenty-nine patients of recurrent small cell lung cancer enrolled in the study.Topotecan was given at the dose of 1.2mg/m^2 on d1-5 and carboplatin was administered at the dose of 300mg/m^2 on d5 in a cycle of 21 days.The patients were evaluated at least after 2 cycles.Results:One patient got complete response and eleven patients got partial response.The overall response rate was 41.38%,and the response rates of sensitive group and refractory groups were 47.62% and 25% respectively.Conclusion:The regimen of topotecan and carboplatin shows better activity in retreated small cell lung cancer patients.The main toxicity is hematological toxicity and can be tolerated.
出处 《现代肿瘤医学》 CAS 2010年第4期718-720,共3页 Journal of Modern Oncology
关键词 拓普替康 卡铂 小细胞肺癌 联合化疗 topotecan carboplatin small cell lung cancer combination chemotherapy
  • 相关文献

参考文献7

二级参考文献20

  • 1Sundstrom S, Bremnes RM, Kasha S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, doxorubicin, and vineristine regimen in small cell lung cancer; Result from a phase Ⅲ trail with 6 years follow up. J Clin Oncol, 2002, 20(26): 4665-4672.
  • 2Von Powel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol, 1999, 91(17): 658-667.
  • 3Eckardt J, Deliverer A, Arizona A, et al. Pooled analysis of topotecan (T) in the second-line treatment of patients (pts) with sensitive small cell lung cancer. Proc Am Soc Clin Oncol, 1997, 16: Abst 1624.
  • 4Creamers G, Grrits C J, Eckardt J, et al. Phase Ⅰ and pharmacological study of oral topotecan administered twice daily for 21 days to adult patients with solid tumours. J Clin Oncol, 1997, 89(15): 1087-1093.
  • 5Gerrits C J, Burris H, Schellens JH, et al. Five days of oral topotecan, a phase Ⅰ and pharmacological study in adult patient with solid tumours. Eur J Cancer, 1998, 34(7): 1030-1035.
  • 6Mary ER, O'Brien, Tudor-Ehade Cudeanu, et al. Phase Ⅲ Trail comparing supportive care alone versus oral topotecan in patients with relapsed small cell lung cancer. J Clin Oncol, 2006, 24(34): 5441-5446.
  • 7Von Powel J, Gatzemeier U, Pujol JL, et al. A phase Ⅱ study of oral versus intravenous topotecan in patient with chemosensitive small cell lung cancer. J Clin Oncol, 2001, 19(6): 1743-1749.
  • 8Aedizzoni A, Manegold C, Debruyne C, et al. A randomised phase Ⅱ study of the efficacy and safety of intravenous topotecan in combination with either eisplatin or etoposide in patients with untreatment as second-line treatment of untreated extensive disease small cell lung cancer. Lung Cancer, 2005, 49(2): 253-261.
  • 9John R, Eckerd, Joachim yon Pawel, et aI. Open-label, muhicenter, randomised, phase Ⅲ study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherpy-naive patients with extensive-disease small cell lung cancer. J Clin Oncol, 2006, 24(13): 2044-2049.
  • 10Schiller JH, Kim K, Hutson P, et al. Phase Ⅱ study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol, 1996,14(8) : 2345-2352.

共引文献6

同被引文献53

  • 1潘显道,王存英.天然抗肿瘤药喜树碱衍生物的研究进展[J].药学学报,2003,38(9):715-720. 被引量:30
  • 2陈茂森,聂立功,李楠,陈建,张红.TE方案与CE方案治疗复发性小细胞肺癌的对比研究[J].临床肿瘤学杂志,2005,10(5):479-480. 被引量:5
  • 3谢春英,刘光金,李凌,刘安文,王顺金.TE方案与EP方案治疗复发性小细胞肺癌[J].实用临床医学(江西),2006,7(8):50-50. 被引量:5
  • 4李艳彦,何永明.TE方案治疗30例复发性小细胞肺癌观察[J].基层医学论坛,2006,10(11):1000-1000. 被引量:5
  • 5PATEL S H, AJLOUNI M, CHAPMAN R, et al. A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non- small cell lung cancer (NSCLC) [ J ]. J Thorac Oncol, 2007, 2(9) : 831-837.
  • 6XIE B F PAN B L.Topotecan in combination with cisplatin in the treatment of head and neck squamous cell carcinoma .重庆医学,2008,37(17):1986-1987.
  • 7O'REILLY E, DONEHOWER R C, ROWINSKY E K, et al. A phase II trial of topotecan in patients with previously untreated pancreatic cancer [ J ]. Anti-Cancer Drugs, 1996, 7 (4) : 410- 414.
  • 8ROWINSKY E K, BAKER S D, BRUKS K, et al. High-dose topotecan with granuloeyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study [J]. Ann Oncol, 1998, 9(2) : 173-180.
  • 9TAYLOR J, AMANZE A, DI FEDERICO E, et al. Irinotecan Use During Pregnancy [ J ]. Obstet Gynecol, 2009, 114 ( 2 ) : 451 -452.
  • 10WANGLY.Antineoplastic Iirinotecan Research Progress .国外医学 药学分册,2004,31(1):7-11.

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部